Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LIPELLA PHARMACEUTICALS INC.

Get SEC filing alerts via email and in your feed for LIPELLA PHARMACEUTICALS INC.

LIPO

LIPELLA PHARMACEUTICALS INC.

About LIPELLA PHARMACEUTICALS INC.

Lipella Pharmaceuticals Inc. is a clinical-stage biotech focused on reformulating existing generic drugs into proprietary, targeted therapies for severe, underserved diseases. Its pipeline includes drug candidates for hemorrhagic cystitis, oral lichen planus, and oral graft-versus-host disease, utilizing a proprietary liposomal delivery platform. The company aims to expedite development through regulatory pathways like orphan and 505(b)(2), targeting rare conditions with high unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from LIPELLA PHARMACEUTICALS INC.

1
1
LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Reports Decline in Revenue and Increased Net Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Reports Increased Losses and Declining Revenues in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Reports Q1 2025 Financial Results with Revenue Decline and Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Reports $5.02 Million Net Loss and $536,000 Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Reports Mixed Financial Results for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments